Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
A phase 2 trial of Emapalumab in Multiple myeloma, run by NYU Langone Health, not yet recruiting.
Overview
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS is a phase 2 interventional study registered as NCT07567014 by NYU Langone Health, with 60 participants planned, started 2026-05-11 and due to reach its primary completion in 2028-05-31. Interventions recorded: Emapalumab. Conditions recorded: Multiple Myeloma, Large B-cell Lymphoma (LBCL).
Linked to the drug Emapalumab because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialEmapalumab Prevention of CAR-T Cell Associated Toxicities
Shares Emapalumab and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Shares Multiple myeloma and the tag pipeline.
- TrialPamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.